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Summary
 
We studied how combination antiviral therapy affects B cell abnormalities associated with
HIV-1 infection, namely elevated circulating immunoglobulin (Ig)G antibody-secreting cell
(ASC) frequencies and hypergammaglobulinemia. Within a few weeks of starting antiviral
therapy, there is a marked decline in IgG-ASC frequency in both acutely and chronically in-
fected people, whereas the hypergammaglobulinemia often present during chronic infection is
more gradually resolved. These reductions are sustained while HIV-1 replication is suppressed.
HIV-1 antigen–specific B cell responses are also affected by therapy, manifested by a rapid de-
cline in circulating gp120-specific ASCs. Anti-gp120 titers slowly decrease in chronically in-
fected individuals and usually fail to mature in acutely infected individuals who were promptly
treated with antiretroviral therapy. Long-term nonprogressors have high titer antibody re-
sponses to HIV-1 antigens, but no detectable gp120-specific IgG-ASC, and normal (or subnor-
mal) levels of total circulating IgG-ASC. Overall, we conclude that HIV-1 infection drives B
cell hyperactivity, and that this polyclonal activation is rapidly responsive to decreases in viral
replication caused by combination antiviral therapy.
Key words: hypergammaglobulinemia • human immunodeﬁciency virus 1 • B cells • 
antiretroviral therapy • antibody
 
I
 
nfection with human immunodeficiency virus type 1
(HIV-1) is associated with several abnormalities of B cell
function (1–6). In consequence, individuals who have been
infected with HIV-1 for several years (chronic infection)
are often hypergammaglobulinemic, with elevations in
plasma IgG of up to twice the normal level (1, 3, 7, 8).
Most of the excess antibody is not HIV-1 antigen–specific,
reflecting instead a generalized, polyclonal activation of B
cell functions caused by systemic HIV-1 infection (1–5).
Consistent with this, B cells from HIV-1–infected people
spontaneously secrete IgG in culture to a much greater ex-
tent than cells from uninfected individuals, yet respond rel-
atively poorly to B cell mitogens in vitro (1, 3). Once they
develop, these abnormalities are sustained throughout the
course of infection. However, what drives them is unclear.
Superimposed on these polyclonal responses are strong,
antigen-specific B cell responses to multiple HIV-1 anti-
gens, the most dominant being to the viral Env (gp120 and
gp41) and Gag (p24 and p17) proteins (9, 10). The antigen-
specific responses are initiated within a few weeks of infec-
tion (seroconversion) and increase in magnitude for 
 
z
 
1 yr
(11–13). However, the anti-Env and anti-Gag responses
differ in the extent to which they are sustained throughout
the course of HIV-1 infection. Anti-Env antibodies are
usually present at high titers even in individuals who
progress to disease, often right until death (11, 14–20). In
contrast, anti-Gag responses are lost (or in some cases never
fully develop) during disease progression; a low anti-Gag
titer is a poor prognostic indicator, associated with low
CD4 T cell counts and high viral loads (11, 14–20). This is
paradoxical considering the lack of antiviral function associ-
ated with anti-Gag antibodies, but it is thought that the de-
cline in the anti-Gag response is a surrogate marker for the
loss of T cell help caused by HIV-1 infection of CD4
 
1
 
 T
cells (11, 16, 18, 20). Why the anti-Env response is so
strongly sustained under these T cell help–depleted condi-
tions is unresolved, but we have suggested that it may reflect
the existence of alternative antigen presentation pathways
for the highly glycosylated envelope glycoproteins (11).
Although the abnormalities in B cell function and the
antigen-specific production of anti–HIV-1 antibodies are
both responses to HIV-1 infection, their dependence on
sustained viral replication has not been defined. Nor is it
clear that they are driven by the same mechanisms. The de-
velopment of combinations of potent antiretroviral drugs
(protease and reverse transcriptase inhibitors) that can sup-
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press HIV-1 replication by several orders of magnitude in
vivo has now allowed us to examine these questions. Spe-
cifically, we have assessed how the different B cell re-
sponses change when viremia is suppressed. We show that
sustained reductions in plasma viremia after antiviral ther-
apy cause the numbers of gp120-specific and total IgG anti-
body-secreting cells (ASC)
 
1
 
 to decline within a few days.
Plasma anti-gp120 and anti-p24 antibody titers in chronically
infected individuals decline much more gradually, and hy-
pergammaglobulinemia is also eventually resolved. When
therapy is initiated during acute HIV-1 infection, the IgG-
ASC frequency again decreases rapidly, and in most cases an-
tigen-specific responses are also diminished or fail to increase.
 
Materials and Methods
 
Study Subjects.
 
Cohort 1 comprised 19 drug-naive individu-
als, 16 of whom were screened for entry into a phase I clinical
trial of an antiviral regimen involving three reverse transcriptase
inhibitors (zidovudine, lamivudine, and abacavir) and one experi-
mental protease inhibitor (141W94) (Table 1). Of these individu-
als, 4 had been infected with HIV-1 for 
 
,
 
90 d (acute infection)
and 12 had been infected for between 4 mo and 12 yr (chronic
infection). The four acutely infected cases and six of the chroni-
cally infected cases met the criteria for entry into the trial, initi-
ated therapy, and were followed longitudinally for up to 30 wk
(21). The remaining six chronically infected individuals did not
participate in the trial, so provide only baseline, pretherapy data.
Also included in cohort 1 are three long-term nonprogressors
(LTNPs), two of whom have been described previously (individu-
als AD-19 and AD-65; references 11, 22). An additional individual
(S006) who had been infected for 1–2 yr had no detectable plasma
viremia (
 
,
 
100 RNA copies/ml in the branched DNA [bDNA]
assay), with a CD4 count of 413. He was not formally included
among the LTNPs in cohort 1 because of the short duration of his
infection, but is referred to in the context of studies on LTNPs as
a prospective slow progressor with undetectable plasma viremia.
All participants gave written informed consent for all the studies
described below. Adherence to therapy was confirmed by inter-
view and by the absence of any resurgence in viral loads, measured
using the bDNA assay. Nonadherence is noted in the text below.
Longitudinal studies that required fresh cells were performed
only on 10 members of cohort 1. However, an additional cohort
 
1
 
Abbreviations used in this paper:
 
 ASC, antibody-secreting cell; bDNA,
branched DNA; LTNP, long-term nonprogressor.
 
Table 1.
 
Baseline CD4 T Cell Counts and Plasma Viral Loads for Cohort 1
 
Patient groups Patient ID Duration of infection CD4 count Plasma viral load Treatment
 
cells/
 
m
 
l HIV-1 RNA copies/ml
 
Acute infection No. 902
 
,
 
90 d 999 383,000 Combination
No. 909
 
*
 
,
 
90 d 734 509 antiretroviral
No. 910
 
,
 
90 d 476 9,168 therapy
No. 911
 
,
 
90 d 685 21,800
Chronic infection No. 889 4 mo 333 9,399 Combination
No. 893 12 yr 181 25,700 antiretroviral
No. 894 6 mo 484
 
‡
 
6,535 therapy
No. 895
 
,
 
1yr 392 16,010
No. 896
 
§
 
.
 
5 yr 12 164,800
No. 897
 
,
 
1yr 392 18,560
Chronic infection S001 1 yr 317 23,000 Untreated
S002 15 mo 224 6,000
S003
 
,
 
1 yr 417 7,800
No. 891 2–3 yr 288 27,360
S004
 
.
 
8 yr 459 4,000
S005 2–3 yr 513 27,570
LTNP LTS-6
 
.
 
12 yr 967
 
,
 
100 Untreated
AD-65
 
i
 
.
 
15 yr 825
 
,
 
100
AD-19
 
i
 
.
 
14 yr 1,053
 
,
 
100
Of the 19 members of cohort 1, 10 were followed longitudinally after starting therapy with three reverse transcriptase inhibitors and one protease in-
hibitor. The CD4 counts given for the LTNPs were measured within the 3-mo period before the assays for ASCs.
 
*
 
Subject was first analyzed within 1 wk of starting therapy.
 
‡
 
CD4 count was determined at 3 wk.
 
§
 
No baseline PBMC sample was available. The first sample obtained for ELISPOT assay was taken 3 wk after therapy began.
 
i
 
These LTNPs have been described previously (11, 21). 
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was also formed. Cohort 2 comprises 13 participants in a phase I
clinical trial of a different 4-drug regimen (reverse transcriptase in-
hibitors zidovudine and lamivudine; protease inhibitors saquinavir
and ritonavir; Table 2). 3 of the participants were acutely infected
with HIV-1, and 10 were chronically infected (23). The median
CD4 count for the 10 chronically infected individuals was 434
cells/
 
m
 
l (range 260–910), and for the 3 acutely infected individu-
als, it was 399 cells/
 
m
 
l (range 136–1,039). Each individual had
been treated for between 16 and 36 wk before this immunologi-
cal study was initiated, so samples were only available for assays
that could be performed prospectively. All 13 participants had
undetectable levels of plasma viremia (
 
,
 
100 RNA copies/ml in
the reverse transcriptase PCR assay) at the time we analyzed their
circulating IgG-ASC frequencies.
From cohorts 1 and 2, individuals no. 896 (cohort 1) and no.
2004 (cohort 2) can be defined as having progressive HIV-1 in-
fection, based on their CD4 counts and viral loads (Tables 1 and 2).
Six uninfected laboratory workers formed a control group rele-
vant to both cohorts 1 and 2.
 
Clinical Assays.
 
Plasma HIV-1 RNA levels were determined
using the bDNA assay (cohort 1; Chiron Mimotopes, San Diego,
CA) or a reverse transcriptase PCR assay from Roche Labs. (co-
hort 2; Nutley, NJ). CD4
 
1
 
 T cell counts were determined by
flow cytometry using directly conjugated mAbs and a FACSCali-
bur
 
Ò
 
 instrument (Becton Dickinson, La Jolla, CA).
 
PBMC Isolation.
 
Venous blood was collected into heparin-
coated tubes. PBMCs were isolated within 4 h of collection by
Ficoll gradient separation. The cells were washed three times (at
1,000 rpm for 10 min) in cold PBS to remove platelets and resus-
pended at 10
 
6
 
/ml in RPMI 1640 medium containing 10% FCS
(R-10 medium).
 
ELISPOT Assay.
 
MultiScreen 96-well filtration plates (Milli-
pore, Bedford, MA) were coated overnight at 4
 
8
 
C with either goat
anti–human IgM Fc or goat anti–human IgG Fc (Sigma Chemical
Co., St. Louis, MO) at 10 
 
m
 
g/ml in PBS (pH 7.4) for detection
of total IgM-specific or IgG-specific ASCs, respectively. For de-
tection of anti-gp120 ASCs, the wells were coated with the sheep
anti-gp120 antibody D7324 (Aalto BioReagents, Dublin, Ireland)
followed by rgp120 JR-FL (a gift from Paul Maddon, Progenics
Pharmaceuticals Inc., Tarrytown, NY) at 100 ng/ml in PBS. To
detect anti-p24 ASCs, the wells were directly coated with glu-
tathione-S-transferase–p24 fusion protein at 5 
 
m
 
g/ml (the vector
construct was a gift from Ian Jones, NERC Institute of Virology,
Oxford, UK). All plates were washed three times with 200 
 
m
 
l of
PBS containing 0.5% Tween 20 (PBS-T), blocked with 3% BSA
in PBS for 30 min at 37
 
8
 
C, and then washed with R-10 medium.
Four serial threefold dilutions of PBMCs from a stock at 10
 
6
 
/ml
were prepared in R-10 medium, and 200 
 
m
 
l aliquots were added
to each well. The plates were incubated overnight at 37
 
8
 
C in a
humidified incubator, and the cells were removed by washing the
wells six times with PBS-T. Antibodies secreted from the cells and
bound to the plate were detected by incubation for 2 h at room
temperature with alkaline phosphatase–conjugated anti–human
IgG Fc (Accurate Chemicals, Westbury, NY) or anti–human
IgM 
 
m
 
 chain (Sigma Chemical Co.), followed by three washes in
PBS-T and one in PBS, and the addition of NBT/BCIP (ni-
troblue tetrazolium chloride/5-bromo-4 chloro-3-indoyl phos-
phate 
 
p
 
-toluidine salt) substrate for 15 min (GIBCO BRL, Gaith-
ersburg, MD). The plates were rinsed in tap water and allowed to
dry before blue spots (positive reactions) were counted using a
dissecting microscope. The ELISPOT assay was highly reproduc-
ible; duplicate samples provided ASC frequencies within twofold
of each other. Control experiments showed that there was negli-
gible binding of cells to wells in the absence of coating antibodies
or antigen.
To monitor the efficiency of the ELISPOT assay, B cell lines
secreting IgG mAbs to gp120 (A32, an Epstein Barr virus–trans-
formed B cell line from James Robinson, Tulane University,
New Orleans, LA) or p24 (1D7, a human heterohybridoma line
from Herman Katinger, Institute of Applied Microbiology, Vi-
enna, Austria) were used as positive controls. Approximately 5%
of the cells from the A32 line and 
 
.
 
50% of the cells from the ID7
line produced ELISPOTS on gp120- or p24-coated plates, re-
spectively; these differing sensitivities are probably attributable to
the much larger size and higher levels of antibody production of
the 1D7 cells. The numbers of spots were approximately twofold
lower when wells were coated with anti-IgG Fc to detect total
IgG. Thus the antigen-specific assay was slightly more sensitive
than the total IgG assay. Subsequent studies showed that use of an
anti-IgG Fab coating antibody (Accurate Chemicals) instead of
the anti-IgG Fc allowed more sensitive detection. However, this
reagent was not used routinely in the clinical studies, so our total
ASC numbers are an underestimate by a factor of approximately
two. This does not affect any of the relative values recorded be-
low.
 
Measurement of Antibodies in Culture Supernatants and Plasma.
 
PBMCs were cultured at 10
 
6
 
/well in 24-well plates in 2 ml of R-10
medium. After 8 d, supernatants were collected and anti-gp120
and anti-p24 antibody titers were measured by ELISA as previ-
ously described (11). Plasma anti-gp120 and anti-p24 titers were
also determined by this method. Titers are presented as the
plasma dilution at which the mid-point of the antibody–antigen
titration curve was reached; low titers were calculated by extrap-
olation, as previously described (11). Total IgG titers in culture
supernatants were measured in the same way except that the
plates were coated with goat anti–human IgG Fc (5 
 
m
 
g/ml;
Sigma Chemical Co.). Total IgG concentrations in plasma were
determined by a commercial laboratory (SmithKline Beecham
Laboratories, Syosset, NY).
 
Statistical Analyses.
 
IgG-ASC and IgM-ASC numbers and
levels of secreted IgG in different groups in cohort 1 were com-
pared using a Mann-Whitney nonparametric test, and
 
 P 
 
values
 
,
 
0.05 are reported. IgG-ASC levels were compared with viral
load and CD4 count using Pearson’s correlation, and 
 
r
 
 values and
 
P 
 
values (
 
,0.05) are recorded. Statistical estimates for the half-life
of IgG-ASC for eight members of cohort 1 were obtained either
by logarithmic linear regression analysis or by determining the
rate of descent between two consecutive time points. Half-lives
for the rate of clearance of excess plasma IgG and the decay in
anti-gp120 and anti-p24 titers were calculated by nonlinear fitting
of an exponential model with a nonzero asymptote. 
Results
Correlation between Circulating IgG-ASC Frequency and
Plasma Viremia in HIV-1–infected Individuals. To measure
the number of circulating ASCs, including those specific
for HIV-1 antigens, we used an ELISPOT assay since this
allows direct quantification of the numbers of B cells acti-
vated in vivo without further cultivation and stimulation
(24, 25). Preliminary experiments indicated that it was nec-
essary to use freshly isolated PBMCs in the ELISPOT assay;
a freeze–thaw cycle or even storing the cells, refrigerated,
overnight resulted in a significant reduction in the ASC237 Morris et al.
Figure 2. Correlation be-
tween the number of IgG-ASCs
and plasma viral load. The 18
drug-naive HIV-1–infected indi-
viduals from cohort 1 were stud-
ied as in Fig. 1. Viral load was
determined using the bDNA as-
say and IgG-ASC frequencies
were determined by ELISPOT.
frequencies recorded. This practical consideration meant
that we could not analyze blood samples retrospectively
with the ELISPOT assay. We therefore studied individuals
who were willing to provide fresh blood on a regular basis.
Baseline ASC frequencies were measured using samples
from 18 of the 19 drug-naive HIV-1–infected individuals
(cohort 1). Subject no. 896 was not included in this analysis
as he had already been receiving therapy for 3 wk before
the availability of the first blood sample so no baseline de-
termination was possible. Of the 18 people studied, 4 had
been infected with HIV-1 for ,90 d (acute infection), 11
for between 4 mo and 12 yr (chronic infection), and 3
were LTNPs (Table 1). ASC frequencies were also deter-
mined in 6 uninfected individuals for comparison. The fre-
quencies of IgG-ASC in both acutely (median 1,683/106
PBMCs) and chronically (2,185/106 PBMCs) infected in-
dividuals were significantly elevated (P ,0.05) compared
with uninfected donors (177/106 PBMCs), although the
range was very broad (Fig. 1 a). However, the LTNPs had
low levels of circulating IgG-ASC (91/106 PBMCs) that
were slightly lower than those in uninfected individuals.
On average, IgG-ASC constituted around 0.2% of total
PBMCs (range 0.03–0.46%) for acutely and chronically in-
fected members of cohort 1.
Unlike IgG-ASC frequencies, IgM-ASC levels were not
significantly elevated in HIV-1–infected individuals; only
three chronically infected people had IgM-ASC frequen-
cies that were higher than those in normal donors (Fig. 1
b). The LTNPs (and also the aviremic individual no. S006)
had no measurable IgM-ASC, whereas all the acutely and
most of the chronically infected individuals and the unin-
fected controls had low, but detectable, levels. Thus, B cell
hyperactivity in HIV-1 infection predominantly comprises
memory B cells expressing surface IgG, reactivated in a
largely non–antigen-specific manner, and is not a more
generalized phenomenon.
In addition to measuring IgG-ASC frequencies by
ELISPOT, we also quantitated spontaneous IgG secretion
from B cells cultured for 8 d. B cells from HIV-1–infected
individuals (other than the LTNPs) secreted significantly
more IgG than B cells from uninfected people (P ,0.05;
Fig. 1 c). There was considerable donor-to-donor variation
in the extent of IgG secretion, which correlated with the
variable IgG-ASC frequencies in the same individuals.
Only a small fraction of the secreted IgG was gp120-spe-
cific, and even less was p24-specific (data not shown). B
cells from the LTNPs did not secrete detectable amounts of
IgG in culture, consistent with the almost complete ab-
sence of IgG-ASC in these cultures.
Comparing the IgG-ASC frequencies in the blood with
plasma HIV-1 RNA levels showed that there was a positive
correlation between these parameters (r 5 0.52, P ,0.05;
Fig. 2). The highest IgG-ASC frequency was found in an
acutely infected individual (no. 902; 4,640 IgG-ASC/106
PBMCs) who also had the highest viral load (383,000
RNA copies/ml). The individuals with the lowest viral
loads (the LTNP and slow progressor no. S006) had almost
undetectable levels of IgG-ASC. A positive correlation was
still evident when the three LTNPs were excluded, but this
no longer reached statistical significance (r 5 0.51, P 5
0.052). In addition, there was no correlation between CD4
count and IgG-ASC frequency, both for the group as a
whole (n 5 18) and when the three LTNPs were excluded.
Antiviral Therapy Rapidly Reduces the Numbers of Circulat-
ing IgG-ASCs. The baseline studies indicated that B cell
hyperactivity (elevated IgG-ASC frequency) was associated
with the extent of HIV-1 replication (plasma viremia). To
determine whether a reduction in viral replication also
lowered the IgG-ASC frequency, we studied four acutely
and six chronically infected individuals from cohort 1 who
participated in a combination antiviral therapy trial involv-
ing one protease inhibitor and three reverse transcriptase
Figure 1. Baseline ASC fre-
quencies and spontaneous IgG
secretion in cohort 1. ASC fre-
quencies were determined in
freshly isolated PBMCs from un-
infected individuals (n 5 6) and
from three groups of individuals
who had been infected with
HIV-1 for varying lengths of
time. All study subjects were
drug naive at the time of assay
except for one individual whose
baseline value could only be de-
termined after 1 wk of therapy
(indicated by asterisk). ELISPOT plates were coated with either (a) anti–human IgG Fc to detect IgG-ASCs or (b) anti–human IgM Fc to detect IgM-ASCs.
(c) Spontaneous IgG secretion after 8 d of culture was also measured by ELISA for the same individuals. Bars represent the median values for each group.238 HIV-1 B Cell Responses during Antiretroviral Therapy
inhibitors. IgG-ASC frequencies were measured longitudi-
nally in these 10 individuals over a 6–20-wk period.
Plasma viremia was rapidly reduced in each recipient of
combination therapy. None of the 10 participants had a de-
tectable viral load after 6 wk of therapy, as determined us-
ing a bDNA assay with a sensitivity limit of z100 HIV-1
RNA copies/ml. This was associated with a substantial re-
duction in the number of circulating IgG-ASCs in each in-
dividual who had an initially elevated level, irrespective of
whether they were acutely or chronically infected (Fig. 3).
By 6–10 wk after therapy was initiated, the median IgG-
ASC frequency for all 10 participants at baseline (2,185/106
PBMCs) had been reduced by 5.8-fold to 378/106 PBMCs,
only slightly elevated compared with the frequency in un-
infected controls (177/106 PBMCs). However, the median
reduction for the seven individuals who had the highest
baseline IgG-ASC frequencies was 8-fold, and the extent of
the reduction could be as high as 29-fold (e.g., no. 902) (Fig.
3 a). The extent of spontaneous IgG secretion from B cells in
culture was also reduced after antiviral therapy, consistent
with the reduction in the circulating IgG-ASC frequency.
Thus, in 10 individuals from cohort 1 who were included
in the trial, the median pretherapy IgG-secretion level was
215 ng/ml, and the post-therapy level was 13 ng/ml (data
not shown).
Subject no. 902’s IgG-ASC frequency declined rapidly as
his viral load dropped (Fig. 3 a). However, before the visit
at week 20 he discontinued the therapeutic regimen for 10 d,
resuming treatment 1 wk before returning to the clinic. A
transient resurgence in IgG-ASC frequency was then noted
at week 20 (Fig. 3 a; asterisk). All other participants re-
ported strict adherence to the regimen and their levels of
IgG-ASC remained depressed during the study period. The
individual with the highest IgG-ASC frequency (no. 896;
751/106 cells) after 8 wk of therapy was chronically in-
fected, with advanced disease and a CD4 count of 12 cells/
ml (Table 1).
The decline in IgG-ASC frequency was usually rapid, ei-
ther coincident with the decline in plasma viremia or com-
mencing shortly thereafter, although the kinetics of the de-
cline varied between individuals (Fig. 4). Data derived
from 8 of the 10 recipients were used to estimate the half-
life of circulating IgG-ASCs (too few data points were
available for no. 909, and reliable data could not be ob-
tained from no. 895). This was calculated to be between 7
and 26 d (1–3.5 wk) with a median of 16 d, and was similar
in both acutely and chronically infected individuals. These
are likely to be minimum estimates, given that viral RNA
can still be measured during the first few weeks of treat-
ment. More frequent sampling of blood during the early
stages of therapy would have refined our estimates, but this
was not always possible.
It should be noted that the above half-lives reflect
changes in the IgG-ASC frequency as a dynamic popula-
tion in the peripheral blood. Thus, we have not deter-
mined whether the decline in IgG-ASC frequency in the
blood, calculated as a half-life above, is due to the death of
these cells, to their reversion to a quiescent state, to their
redistribution into other tissue compartments, or to a re-
duction in the generation of new IgG-ASCs. Any or all of
these factors could contribute to the overall reduction in
IgG-ASC frequency observed, and to the rate at which it
occurs.
Sustained Reduction in IgG-ASC Frequency after Antiviral
Therapy. To determine whether the reduction in circulat-
ing IgG-ASCs caused by combination therapy was a pro-
longed effect, we studied a separate cohort who had been
receiving combination therapy for up to 36 wk (cohort 2).
The 10 chronically infected individuals had been treated
with a 4-drug regimen for between 32 and 36 wk, includ-
ing two reverse transcriptase inhibitors and two protease
inhibitors. Since the ELISPOT assay can only be per-
formed on freshly isolated PBMCs, we were unable to de-
termine baseline IgG-ASC frequencies retrospectively for
cohort 2. However, it is reasonable to assume that it would
have been broadly comparable to the baseline level in the
chronically infected members of cohort 1 (2,185 IgG-ASC/
106 PBMCs). The median IgG-ASC frequency in cohort 2
after 32–36 wk of therapy was low (339/106 PBMCs), and
comparable to that in cohort 1 after 6–8 wk of therapy (378/
Figure 3. Longitudinal analysis of the
effects of antiretroviral therapy on IgG-
ASC frequency. Four acutely infected
and six chronically infected individuals
from cohort 1 were studied. Baseline
data were not available from subjects no.
909 and no. 896, so the first data points
are from wk 1 and 3 after therapy was
initiated, respectively.239 Morris et al.
106 PBMCs). This suggests that the rapid reduction in B cell
hyperactivity upon therapy is indeed a sustained effect.
The median IgG-ASC frequency in three acutely infected
individuals treated for 16–36 wk with this second 4-drug
regimen (cohort 2) was also low (292/106 PBMCs), and
very similar to the median for individuals treated during
acute infection in cohort 1 (291/106 PBMCs). However,
one individual (no. 2004) still had a high IgG-ASC fre-
quency after 16 wk of therapy (898 IgG-ASC/106 PBMCs).
This individual also had a low CD4 T cell count (136 cells/
ml). This profile is similar to individual no. 896 in cohort 1
who also had progressive infection (Figs. 3 b and 4 b);
whether this poor response to antiretroviral therapy will be
the norm for individuals with advanced disease will require
further studies. The presence of elevated number of IgG-
ASCs in these two individuals after therapy does, however,
suggest that the reductions in IgG-ASC frequencies seen in
other cases are not due to a direct effect of the antiviral
drugs on B cells.
HIV-1 Antigen–specific IgG-ASC Frequencies and Specific An-
tibody Titers: Responses to Antiviral Therapy. To see whether
antiviral therapy also affected HIV-1 antigen–specific B cell
responses in our study cohorts, we determined the frequen-
cies of IgG-ASC specific for gp120 and p24, and the plasma
antibody titers to the same proteins. Specific IgG-ASC fre-
quencies were measured by ELISPOT using plates coated
with recombinant gp120 or p24 proteins. Antibody titers
were determined by ELISA, using the same proteins.
At baseline, most members of cohort 1 had low levels of
gp120-specific IgG-ASC, which constituted only a minor
proportion of the total number of IgG-ASCs (Fig. 5 and
data not shown). Only two of the four acutely infected in-
dividuals had a detectable level of gp120-specific IgG-
ASCs (16 and 5 anti-gp120 ASC/106 PBMCs, respectively;
,0.2% of total IgG-ASCs), whereas none of the LTNPs
did. Anti-gp120 IgG-ASCs were present at greater fre-
quency in the chronically infected individuals (Fig. 5 b and
data not shown); 8 of the 11 had from 15 to 429 anti-
gp120 ASCs/106 PBMCs, equivalent to 0.6–14.9% of the
total IgG-ASCs.
The three chronically infected individuals whose circu-
lating gp120-specific IgG-ASC frequency exceeded 5% of
the total IgG-ASCs responded to antiviral therapy by losing
all detectable gp120-specific IgG-ASCs within 3 wk, and
this loss persisted for the duration of the study (Fig. 5 b).
Consistent with this, only 3 of the 10 chronically infected
individuals who had been treated for 36 wk (cohort 2) had
detectable gp120-specific IgG-ASCs, and then only at very
low levels (,20/106 PBMCs). The proportion of IgG-
ASC specific for p24 was even lower than that for gp120;
these cells were detected in only four drug-naive subjects
(one acute and three chronic) from cohort 1 (Fig. 5 and
data not shown). After treatment, anti-p24 IgG-ASCs were
no longer detectable in these individuals, nor could any be
detected in either the members of cohort 2 who had been
treated for a longer period or the LTNPs.
Despite the reductions in HIV-1 antigen–specific IgG-
ASC frequencies after therapy was initiated, the plasma
anti-gp120 and anti-p24 antibody titers in most members
of cohort 1 did not decline significantly over the 12–30-wk
study period (Fig. 5). In one subject (no. 902), the antibody
titers actually continued to increase at a time when the
numbers of circulating anti-gp120 ASCs were declining.
However, this individual was poorly adherent to antiviral
therapy and showed a later resurgence in both total IgG-
ASCs (Fig. 3 a) and gp120-specific IgG-ASCs, as well as
Figure 4. Effects of antiretroviral therapy on IgG-ASC frequencies and
viral load. Longitudinal IgG-ASC and viral load data for (a) four acutely
and (b) six chronically infected individuals from cohort 1. Antiviral ther-
apy was initiated on day 0. Baseline ASC data were not available from
subjects no. 909 and no. 896, so the first data points are from wk 1 and 3
after therapy was initiated, respectively. The half-lives of IgG-ASCs are
indicated on the figures for nine of the individuals. Note that, unlike in
Fig. 3, the IgG-ASC frequencies are plotted on different scales for each
individual, in order to depict the rates of change of ASC frequency with
maximum clarity.240 HIV-1 B Cell Responses during Antiretroviral Therapy
the sustained anti-gp120 titer increase (Fig. 5 a). This may
limit any inferences that can be drawn.
The data presented in Fig. 5 suggest that there is little re-
lationship between plasma antibody levels and the fre-
quency of antigen-specific and -nonspecific ASCs in pe-
ripheral blood. We confirmed this by directly comparing
these parameters. Total plasma IgG concentrations and the
frequency of total IgG-ASCs in the 18 examined members
of cohort 1 (pretherapy values) are not correlated (Fig. 6 a).
This is because infection for ,1 yr is often associated with
a high circulating IgG-ASC frequency in the absence of
hypergammaglobulinemia, which presumably takes some
time to develop. For most individuals, there was no corre-
lation between the anti-gp120 IgG-ASC frequency and the
anti-gp120 antibody titers (Fig. 6 b). Individuals with the
highest anti-gp120 and anti-p24 titers (LTNPs) had no cir-
culating gp120- or p24-specific IgG-ASCs (Fig. 6 b and
data not shown). However, one acutely infected individual
(no. 911) with no detectable anti-gp120 antibodies also had
no detectable gp120-specific IgG-ASCs. In addition, the
chronically infected individual with the highest anti-gp120
titer (no. 893) also had the highest gp120-specific IgG-
ASC frequency. Both these outliers (no. 911 and no. 893)
are marked by asterisks on Fig. 6 b. Their inclusion in the
data set does allow a correlation between anti-gp120 IgG-
Figure 5. Effects of antiretroviral therapy on HIV-1–specific antibody
titer and ASC frequency. Depicted are plasma anti-gp120 (d) and anti-
p24 (m) midpoint antibody titers and gp120- (s) and p24-specific (n)
ASC frequencies, in (a) four acutely infected and (b) six chronically in-
fected individuals from cohort 1. Antiviral therapy was initiated on day 0.
The first data point for subject no. 909 is from 1 wk after therapy began.
Fresh PBMCs were not available from individual no. 896 on day 0 for
ASC frequency determination.
Figure 6. Relationship between circulating IgG-ASC frequencies and
plasma antibody titers. (a) Baseline IgG-ASC frequencies are compared
with plasma IgG concentrations; (b) circulating anti-gp120 IgG-ASC fre-
quencies are compared with anti-gp120 antibody titers; for 18 members of
cohort 1, including 4 acutely (m) and 11 chronically (d) infected individ-
uals and 3 LTNPs (s). See text for information on asterisked individual.241 Morris et al.
ASC frequency and anti-gp120 titer to be made (r 5 0.81;
P ,0.01). However, we have reservations about the gener-
ality of this apparent correlation since omission of the outli-
ers generated an r value of 20.17, which is not significant.
Antiretroviral Therapy Resolves Hypergammaglobulinemia and
Diminishes HIV-1–specific Antibody Responses. Hypergamma-
globulinemia (plasma IgG levels .16.2 mg/ml in Cauca-
sians) is a manifestation of chronic HIV-1 infection but
usually takes time to develop. Only the two members of
cohort 1 who had been infected for at least 5 yr (nos. 893
and 896) were hypergammaglobulinemic; neither the
acutely infected individuals nor those infected for ,5 yr
had elevated plasma IgG levels despite having high IgG-
ASC frequencies (Fig. 1). After antiviral therapy was initi-
ated, both of these individuals remained hypergammaglob-
ulinemic over a 16-wk period, despite the rapid reduction
in IgG-ASC frequency (Figs. 3 and 4). No later samples
were available from these individuals.
Both baseline and longitudinal studies of plasma IgG lev-
els could be performed on cohort 2, since IgG concentra-
tions can be determined retrospectively from frozen sam-
ples. This allowed us to study changes in plasma IgG
concentrations over a longer period of time. At baseline, 5
of the 10 chronically infected individuals had IgG levels
.16.2 mg/ml (Table 2). After 32–36 wk of therapy,
plasma IgG concentrations were reduced in all 10 partici-
pants, including those not originally considered to be hy-
pergammaglobulinemic (Table 2). The most pronounced
falls in plasma IgG were observed in the two African-
American participants (nos. 1007 and 1008), although their
levels were still high at the end of the study (18.5 and 18.6
mg/ml, respectively). However, African-Americans have
naturally higher plasma IgG concentrations than do Cauca-
sians (7, 8), so the post-therapy level observed may not be
abnormal for these two individuals. There were also minor
reductions in plasma IgG concentrations in the three
acutely infected individuals after therapy (Table 2).
Taken together, the studies on cohorts 1 and 2 indicate
that hypergammaglobulinemia is resolved by combination
antiviral therapy, but not as rapidly as is the reduction in
IgG-ASC frequency. This is not surprising since the half-
life of IgG in plasma is z3 wk (26), so it would take some
time for a reduction in plasma IgG to be manifested, even if
all excess IgG production were simultaneously stopped.
However, little or no reduction in plasma IgG levels was
observed in two members of cohort 1 after 16 wk of ther-
apy (five IgG half-lives), implying that hypergammaglobu-
linemia is not as quickly resolved as it theoretically could be
if all the excess IgG production were due to circulating
IgG-ASCs. Since plasma IgG concentrations were reduced
in all members of cohort 2 after 32–36 wk (Table 2), we
determined more accurately the kinetics of the decline in
the four individuals with the greatest initial plasma IgG lev-
els (nos. 1007, 1008, 1010, and 1013; Fig. 7). After ther-
apy, plasma IgG concentrations decayed to a relatively sta-
ble level that was within the normal range for Caucasians
(or African-Americans, as appropriate). Although there was
a degree of scatter in the longitudinal profiles, calculations
of the rate of clearance of the excess IgG indicated that the
minimal estimate for the half-life was in the range of 4–12
wk for three individuals, and 34 wk for the fourth (no.
1008; Fig. 7; see legend for individual values).
Longitudinal analyses of the changes in specific antibody
titer were also performed on members of cohort 2 (Table
2, Fig. 7). Pre- and post-therapy anti-gp120 and anti-p24
titers are recorded for each member of the cohort, along
with the extent of the decreases in each parameter during
the period of therapy (Table 2). Anti-gp120 and anti-p24
titers declined in almost all individuals, but generally to
only a modest extent (median declines were approximately
threefold). The rate of decline in anti-gp120 titer was esti-
mated for the four individuals in whom the kinetics of ex-
cess IgG clearance were also studied (Fig. 7). The half-life
of the anti-gp120 titer reduction was 7–21 wk, and for
those three individuals with measurable titers the half-life
of anti-p24 titer reduction was 9–15 wk.
Discussion
The main purpose of this study was to explore how
HIV-1–specific and –nonspecific B cell responses were af-
fected by combination antiretroviral therapy. We sampled
only the peripheral blood to avoid invasive procedures, so
all conclusions we draw refer specifically to this compart-
ment. Nonetheless, the effects of antiviral therapy on the
cells of the peripheral blood may mirror, at least qualita-
tively, effects on cells in other tissues, such as lymph nodes
and bone marrow.
Figure 7. Effect of combina-
tion antiviral therapy on plasma
IgG concentration and specific
antibody titers in cohort 2. Four
chronically infected individuals
were treated for z1 yr. Plasma
anti-gp120 titers (d), anti-p24
titers (m), and total plasma IgG
concentrations (1) are shown.
Estimated half-lives for the decay
in excess total IgG, anti-gp120,
and anti-p24 and for each indi-
vidual were, respectively: no.
1007, 12, 7, and 9 wk; no. 1004,
9 and 15 wk; no. 1010, 4, 21,
and 9 wk; no. 1013, 6, 16 and
not applicable (no anti-p24 titer).242 HIV-1 B Cell Responses during Antiretroviral Therapy
B cell abnormalities associated with HIV-1 infection are
manifested by a significantly elevated frequency of HIV-1
antigen–nonspecific IgG-ASCs in the peripheral blood and
by hypergammaglobulinemia (1–6). These are probably as-
sociated phenomena in that overproduction of IgG by cir-
culating ASCs will tend to increase plasma IgG concentra-
tions, but they are not inevitably linked to one another.
Thus, IgG-ASC frequencies are significantly elevated in
acutely infected individuals, but without hypergammaglob-
ulinemia, whereas both parameters are often increased dur-
ing chronic infection. Overall, IgG-ASC frequency was
not correlated with plasma IgG concentration. Either cir-
culating IgG-ASCs make a negligible contribution to total
plasma IgG, so that an increase in their frequency is incon-
sequential, or else there is an increase in the rate of IgG
clearance to compensate; the steady state plasma IgG con-
centration obviously reflects a balance between IgG pro-
duction and clearance. The capacity of the IgG-clearance
mechanism(s) may, at some stage, be directly or indirectly
affected by systemic HIV-1 infection. Defects in the reticu-
loendothelial system associated with IgG clearance have
been reported to be a complication of advanced HIV-1 in-
fection (27, 28); these might contribute to hypergamma-
globulinemia.
Antiviral therapy that causes substantial reductions in
HIV-1 viremia has a rapid effect on antigen-specific and
-nonspecific IgG-ASC frequencies during both acute and
chronic infection. Coincident with, or soon after, therapy-
induced declines in plasma viremia, IgG-ASCs start to dis-
appear from the blood, with a half-life of only a few weeks.
The IgG-ASC frequency then remains at low levels for
prolonged periods, provided antiviral therapy continues to
suppress HIV-1 replication. In one individual (no. 902)
who was poorly compliant with therapy, there was a rapid
rebound in the numbers of circulating IgG-ASCs. Hyper-
gammaglobulinemia is also resolved by antiviral therapy,
with a half-life of 4–34 wk. This was somewhat longer
than the half-life of IgG secretion from the IgG-ASC pop-
ulation isolated from the peripheral blood (1–3.5 wk), but
the half-life of plasma IgG molecules (z3 wk in uninfected
people; 26) must also be taken into account. Even if excess
IgG production were instantly and completely stopped,
which is obviously not the case, it would still take several
weeks for a significant reduction in plasma IgG concentration
to be manifested. In practice, production of polyclonal IgG
molecules in some compartment that is not in equilibrium
with the blood is likely to be sustained for some time. Re-
sidual viral antigen production due to incompletely effec-
tive antiviral therapy could be a contributory factor here, as
could the presence of persistent antigen trapped on follicu-
lar dendritic cells. In addition, abnormally slow clearance of
IgG from plasma could, in principle, contribute to the
maintenance of high plasma IgG levels in some chronically
infected individuals (see above).
How could a reduction in HIV-1 replication decrease
the circulating IgG-ASC frequency? There are several pos-
sibilities: (a) these cells die; (b) they are redistributed to an-
other body compartment; (c) cellular activation to secrete
IgG is directly or indirectly dependent on continued HIV-1
replication; or (d) new ASCs are not induced. We cannot
discriminate between these possibilities, but we note that
there is a correlation between the circulating IgG-ASC fre-
quency and the level of plasma viremia before therapy.
This tends to argue against the redistribution hypothesis,
and in favor of a relationship (direct or otherwise) between
the production of HIV-1 antigens and antibody secretion
from circulating B cells. The resurgence of the IgG-ASC
frequency in no. 902 during a period of poor compliance is
also consistent with the latter theory (since no increase in
plasma viremia was detected in no. 902 during this period,
we presume that HIV-1 replication in lymphoid tissues was
responsible).
But how might HIV-1 replication affect B cell function
in vivo? HIV-1 antigen load could obviously be an influ-
ence on antigen-specific IgG-ASCs, but the majority of
circulating IgG-ASCs are not specific for HIV-1 antigens
yet are sensitive to a lowering in their concentration. Al-
though HIV-1 has been reported to contain a superanti-
gen(s) (29, 30), this is controversial and the balance of the
evidence is not compelling (31, 32). HIV-1 has also been
reported to directly activate B cells in vitro (33, 34), and in
one study this effect was reported to be mediated by the
COOH terminus of gp41 (35). However, nonspecific acti-
vation of the immune system appears to be a phenomenon
common to many viral infections (36, 37). In particular,
simian immunodeficiency virus infection of macaques is as-
sociated with a generalized activation of B as well as T cells,
leading to a significant increase in the rate of B cell turn-
over in infected animals (37). Thus, further investigations
should not be limited to effects triggered specifically by
HIV-1 antigens. Another possibility is that HIV-1 replica-
tion in CD41 T cells or macrophages causes the secretion
of a cytokine such as IL-6 that activates IgG secretion from
B cells (38–40), and that the reduction in HIV-1 replica-
tion interrupts the production of this cytokine(s). In one
individual, we have been able to monitor changes in the
plasma IL-6 concentrations that mirror changes in plasma
viremia (Binley, J.M., and J.P. Moore, unpublished obser-
vations), but this requires further investigation.
For most individuals, there was no correlation between
circulating anti-gp120 IgG-ASC frequencies and plasma
anti-gp120 antibody titers. This is not surprising since most
specific antibody production occurs outside the blood,
probably by long-lived plasma cells in the bone marrow
(41–45), but it does expose the limitations in sampling cir-
culating IgG-ASCs when trying to dissect the specific hu-
moral immune response to HIV-1 infection. Antigen-spe-
cific B cell functions were also affected by antiviral therapy.
As with the nonspecific IgG-ASCs, gp120-specific IgG-
ASC frequencies decreased rapidly when antiviral therapy
began, in both acutely and chronically infected individuals,
but this was not accompanied by a decrease in plasma anti-
gp120 titer over the same time period. Indeed, in one
acutely infected individual (no. 902), the anti-gp120 titer243 Morris et al.
continued to increase during a period when there was a
marked decline in his circulating gp120-specific IgG-ASC
frequency. Since subject no. 902 was not hypergamma-
globulinemic, the increase in his anti-gp120 antibody titer
has little to do with any defect in IgG clearance; instead, it
may reflect the continued production of anti-gp120 antibod-
ies by plasma cells in bone marrow in a manner insensitive to
reductions in HIV-1 replication (11). Alternatively, it may
be related to this individual’s poor adherence to therapy.
The more prolonged therapy provided to the members
of cohort 2 was accompanied by a gradual decline in anti-
gp120 and anti-p24 titers. But this decrease was usually
only modest, approximately threefold on average. Further-
more, it is not yet clear whether the specific titers in chron-
ically infected people are continuing to decline, or have
stabilized at a reduced level; the present indications favor
the latter interpretation but more protracted studies are re-
quired to be sure of this. The half-lives of the anti-gp120
and anti-p24 titer declines were in the range of 7–21 wk.
These are somewhat longer than the fall in the circulating
gp120- and p24-specific IgG-ASC frequencies, probably
for reasons similar to those discussed above in the context
of the relationship between total IgG-ASC frequency and
hypergammaglobulinemia. Although the relative rates of
decline of total IgG and HIV-1 antigen–specific IgG dif-
fered between the four individuals, it is likely that the grad-
ual reductions in anti-gp120 and anti-p24 titers are related
to the decrease in plasma IgG concentration, rather than to
any specific effect on HIV-1 antibody production.
Studies on the three LTNPs were particularly informa-
tive. These individuals had essentially undetectable levels of
circulating gp120-specific IgG-ASCs, yet very high titers of
anti-gp120 and anti-p24 antibodies. This is, in itself, strong
evidence that circulating IgG-ASCs make little or no con-
tribution to the overall production of antigen-specific anti-
bodies during HIV-1 infection. Indeed, the appearance of
large quantities of antigen-specific ASCs in the blood may
be a pathological consequence of HIV-1 replication, and an
early one at that, although perhaps of relatively benign
consequence. The aviremic individual (no. S006) and the
three LTNPs also had normal (indeed slightly subnormal)
levels of total IgG-ASCs (and also IgM-ASCs), consistent
with their normal plasma IgG concentrations. Thus, al-
though the LTNPs have been HIV-1 infected for up to
15 yr, they show no abnormalities of B cell function.
Therefore, the latter is not an inevitable consequence of
HIV-1 infection, nor of the antibody response that is gen-
erated to HIV-1 antigens. The limited studies on individual
no. S006 (infected for only 1–2 yr but also with undetectable
plasma viremia) indicated that his B cell–mediated responses
were indistinguishable from those in the three LTNPs.
Thus, B cell abnormalities are associated with progressive
HIV-1 infection and the extensive viral replication that is
intimately associated with its pathology. These abnormali-
ties are resolved by effective antiviral therapy, and the effect
is sustained while viremia remains suppressed. This seems
encouraging for the prospects of repairing at least some of
the damage to normal immune functions caused by HIV-1
infection. In addition, the reduction in B cell hyperactivity
may also result in a lowering of the incidence of B cell lym-
phoma during HIV-1 infection.
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